HPV vaccination in France: uptake, costs and issues for the National Health Insurance (Q83554391)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

HPV vaccination in France: uptake, costs and issues for the National Health Insurance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Jean-Paul Fagot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Aurélie Boutrelle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Philippe Ricordeau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Alain Weill

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Hubert Allemand

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

5 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

3610-3616

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Pharmacoepidemiological research using French reimbursement databases: yes we can!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

French national health insurance information system and the permanent beneficiaries sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Modeling cervical cancer prevention in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.064

10.1016/J.VACCINE.2011.02.064

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21382486%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference